Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia

Abstract

The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.

1 - 49 . (canceled)  
   
   
       50 . A pharmaceutical composition comprising a therapeuticallyeffective amount of the (−) stereoisomer of a compound of the formula:  
     
       
         
         
             
             
         
       
     
     or its pharmaceutically acceptable salt, wherein said formula R 2  is a hydrogen, C 2  -C 12  aliphatic alcohol that can or can not contain one or more double bonds and can or can not contain branched carbons and lower alkanamido lower alkyl, and the (−) stereoisomer of the compound is substantially free of its (+) stereoisomer, and wherein the composition is formulated for oral administration in unit dose format.  
   
   
       51 . The composition of  claim 50 , wherein the (−) stereoisomer is (−)2-acetamidoethyl 4-chlorophenyl-(3-trifluoromethylphenoxy)-acetate or (−)4-chlorophenyl-(3-trifluoromethylphenoxy)-acetic acid.  
   
   
       52 . The composition of  claim 50 , wherein the composition comprises a at least one filler and cross-linked polyvinylpyrrolidone.  
   
   
       53 . The composition of  claim 52 , wherein the filler comprises a starch.  
   
   
       54 . The composition of  claim 52 , wherein the filler comprises a cellulose preparation.  
   
   
       55 . The composition of  claim 52 , wherein the filler comprises a starch and a cellulose preparation.  
   
   
       56 . The composition of  claim 50 , wherein the composition comprises a filler, a binder and a lubricant.  
   
   
       57 . The composition of  claim 56 , wherein the lubricant is magnesium stearate.  
   
   
       58 . The composition of  claim 56 , wherein the binder is a starch.  
   
   
       59 . The composition of  claim 57 , wherein the binder is a starch.  
   
   
       60 . The composition of  claim 50 , wherein the composition is in the form of a tablet.  
   
   
       61 . The composition of  claim 55 , wherein the (−) stereoisomer is (−)2-acetamidoethyl 4-chlorophenyl-(3-trifluoromethylphenoxy)-acetate or (−)4-chlorophenyl-(3-trifluoromethylphenoxy)-acetic acid.  
   
   
       62 . The composition of  claim 61 , wherein the (−) stereoisomer and the (+) stereoisomer are in an enantiomeric ratio of at least 98%.  
   
   
       63 . The composition of  claim 59 , wherein the (−) stereoisomer is (−)2-acetamidoethyl 4-chlorophenyl-(3-trifluoromethylphenoxy)-acetate or (−)4-chlorophenyl-(3-trifluoromethylphenoxy)-acetic acid.  
   
   
       64 . The composition of  claim 63 , wherein the (−) stereiosimer and the (+) stereoisomer are in an enantiomeric ratio of at least 98%.  
   
   
       65 . The composition of  claim 50 , wherein the therapeutically effective amount is from 10 to about 1500 mg.  
   
   
       66 . The composition of  claim 62 , wherein the therapeutically effective amount is from 100 to 3000 mg.  
   
   
       67 . The composition of  claim 62 , wherein the therapeutic amount is from 100 to 500 mg.  
   
   
       68 . The composition of  claim 64 , wherein the therapeutically effective amount is from about 100 to 3000 mg.  
   
   
       69 . The composition of  claim 64 , wherein the therapeutic amount is from 100 to 500 mg.  
   
   
       70 . The composition of  claim 50 , wherein the composition is in solid format.  
   
   
       71 . The composition of  claim 50 , wherein the composition is in the form of a tablet, capsule, pill, powder, granule, or dragee core.  
   
   
       72 . The composition of  claim 50 , wherein the composition comprises a filler, a binder, a lubricant and a stabilizer.  
   
   
       73 . The composition of  claim 72 , wherein the composition further comprises polyethylene glycol.